Qing Lin

US Patent:

8114958, Feb 14, 2012

Filed:

Feb 11, 2005

Appl. No.:

10/589054

Inventors:

Christopher J. Soares - La Jolla CA, US
Michael R. Hanley - Corte Madera CA, US
Diana Y. Lewis - San Diego CA, US
David Geoffrey Parkes - Del Mar CA, US
Carolyn M. Jodka - Encinitas CA, US
Kathryn S. Prickett - Foster City CA, US
Soumitra S. Ghosh - San Diego CA, US
Christine Marie Mack - San Diego CA, US
Qing Lin - Getzville NY, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07K 19/00
C07K 14/435
A61K 38/16
A61P 3/04

US Classification:

530307, 530324, 514 49, 514 119, 514909, 536 234

Abstract:

The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

US Patent:

8598120, Dec 3, 2013

Filed:

Feb 1, 2012

Appl. No.:

13/364250

Inventors:

Christopher J. Soares - La Jolla CA, US
Michael R. Hanley - Corte Madera CA, US
Diana Y. Lewis - San Diego CA, US
David G. Parkes - Del Mar CA, US
Carolyn M. Jodka - Encinitas CA, US
Kathryn S. Prickett - Foster City CA, US
Soumitra S. Ghosh - San Diego CA, US
Christine M. Mack - San Diego CA, US
Qing Lin - Getzville NY, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE

International Classification:

A61K 38/16
A61P 3/04
A61P 5/22
C07K 14/435
C07K 19/00

US Classification:

514 119, 435 697, 514 49, 514909, 530307, 530329, 536 234, 930 60

Abstract:

The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

US Patent:

8598314, Dec 3, 2013

Filed:

Sep 26, 2008

Appl. No.:

12/680539

Inventors:

Soumitra S. Ghosh - San Diego CA, US
Josue Alfaro-Lopez - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Odile Esther Levy - San Diego CA, US
Qing Lin - San Diego CA, US
Christopher J. Soares - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE

International Classification:

A61K 38/00
C07K 5/00
C07K 7/00
C07K 16/00
C07K 17/00

US Classification:

530324, 530325, 530326

Abstract:

Peptide-peptidase inhibitor conjugate molecules and methods of manufacture thereof are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.

US Patent:

20090186817, Jul 23, 2009

Filed:

Mar 21, 2007

Appl. No.:

12/293389

Inventors:

Soumitra S. Ghosh - San Diego CA, US
Josue Alfaro-Lopez - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Odile Esther Levy - San Diego CA, US
Qing Lin - Buffalo NY, US
Christopher J. Soares - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/22
C07K 2/00
C07K 14/575

US Classification:

514 12, 530300, 530324

Abstract:

Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.

US Patent:

20100029554, Feb 4, 2010

Filed:

May 25, 2007

Appl. No.:

12/301199

Inventors:

Soumitra S. Ghosh - San Diego CA, US
Diana Y. Lewis - Los Angeles CA, US
Samuel Janssen - San Diego CA, US
Ved Srivastava - San Diego CA, US
Que Liu - San Diego CA, US
Carolyn M. Jodka - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Qing Lin - Buffalo NY, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego

International Classification:

A61K 38/16
C07K 14/00
A61P 3/00
A61P 9/00

US Classification:

514 12, 530324

Abstract:

Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in the methods described herein are also disclosed. Further provided are compositions and methods for the treatment and/or prevention of diabetes mellitus, hyperglycemia, insulin resistance and obesity, and for the reduction of food intake and suppression of appetite of subjects.

US Patent:

20100292172, Nov 18, 2010

Filed:

May 21, 2010

Appl. No.:

12/785396

Inventors:

SOUMITRA S. GHOSH - SAN DIEGO CA, US
JOSUE ALFARO-LOPEZ - SAN DIEGO CA, US
LAWRENCE J. D'SOUZA - SAN DIEGO CA, US
ODILE ESTHER LEVY - SAN DIEGO CA, US
QING LIN - BUFFALO NY, US
CHRISTOPHER J. SOARES - SAN DIEGO CA, US

Assignee:

AMYLIN PHARMACEUTICALS, INC. - SAN DIEGO CA

International Classification:

A61K 38/17
C07K 14/575
C07K 14/46
A61K 38/22
A61P 1/00
A61P 9/00

US Classification:

514 213, 530324

Abstract:

Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.

US Patent:

20140035184, Feb 6, 2014

Filed:

Oct 8, 2013

Appl. No.:

14/048255

Inventors:

Jane Guo Shiah - Irvine CA, US
Qing Lin - Fremont CA, US

International Classification:

A61K 47/34

US Classification:

264145

Abstract:

Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.

US Patent:

20200342556, Oct 29, 2020

Filed:

Apr 25, 2019

Appl. No.:

16/395112

Inventors:

- Roseville MN, US
Qing Lin - San Diego CA, US

International Classification:

G06Q 50/26
G06Q 40/00
G06F 17/27

Abstract:

A system and method includes soft-segment based rules optimization that can mitigate the overall false positives while maintaining 100% true positive detection. The soft clustering allows real-time re-assignment of an account to a dominate archetype behavior, as well as rule optimization based on a logical order with more relaxation on thresholds for the most inefficient rules is performed within each archetype. The rule optimization provides false positive reduction compared to a baseline rule system. The method can be used to reduce false positives for any rule-based detection system in which the same true positive detection is required.